Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 Jun 14;90(12):2326-31.
doi: 10.1038/sj.bjc.6601870.

Use of neoadjuvant chemotherapy prior to radical hysterectomy in cervical cancer: monitoring tumour shrinkage and molecular profile on magnetic resonance and assessment of 3-year outcome

N M deSouza  1 , W P Soutter, G Rustin, M M Mahon, B Jones, R Dina, G A McIndoe
Affiliations
Clinical Trial

Use of neoadjuvant chemotherapy prior to radical hysterectomy in cervical cancer: monitoring tumour shrinkage and molecular profile on magnetic resonance and assessment of 3-year outcome

N M deSouza et al. Br J Cancer. .

Abstract

The objective of this study is to assess tumour response to neoadjuvant chemotherapy prior to radical hysterectomy in cervical cancer using magnetic resonance (MR) to monitor tumour volume and changes in molecular profile and to compare the survival to that of a control group. Eligibility included Stage Ib-IIb previously untreated cervical tumours >10 cm(3). Neoadjuvant chemotherapy in 22 patients (methotrexate 300 mg x m(-2) (with folinic acid rescue), bleomycin 30 mg x m(-2), cisplatin 60 mg m(-2)) was repeated twice weekly for three courses and followed by radical hysterectomy. Post-operative radiotherapy was given in 14 cases. A total of 23 patients treated either with radical surgery or chemoradiotherapy over the same time period comprised the nonrandomised control group. MR scans before and after neoadjuvant chemotherapy and in the control group documented tumour volume on imaging and metabolites on in vivo spectroscopy. Changes were compared using a paired t-test. Survival was calculated using the Kaplan-Meier method. There were no significant differences between the neoadjuvant chemotherapy and control groups in age (mean, s.d. 43.3+/-10, 44.7+/-8.5 years, respectively, P=0.63) or tumour volume (medians, quartiles 35.8, 17.8, 57.7 cm(3) vs 23.0, 15.0, 37.0 cm(3), respectively, P=0.068). The reduction in tumour volume post-chemotherapy (median, quartiles 7.5, 3.0, 19.0 cm(3)) was significant (P=0.002). The reduction in -CH(2) triglyceride approached significance (P=0.05), but other metabolites were unchanged. The 3-year survival in the chemotherapy group (49.1%) was not significantly different from the control group (46%, P=0.94). There is a significant reduction in tumour volume and -CH(2) triglyceride levels after neoadjuvant chemotherapy, but there is no survival advantage.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Tumour volumes pre and post neoadjuvant chemotherapy, showing response in individual cases.
Figure 2
Figure 2
Sagittal T2-weighted fast spin-echo (FSE 3000/88 ms (TR/effective TE)) images before (A) and after (B) three cycles of neoadjuvant chemotherapy. The intermediate signal intensity tumour confined to the cervix (arrows) reduced from 50 to 18 cm3 in volume.
Figure 3
Figure 3
Tumour volume distribution prior to treatment in the neoadjuvant chemotherapy group and the control group.
Figure 4
Figure 4
Proton magnetic resonance spectra (1H PRESS, TR=1600 ms; TE=135 ms) acquired from a 3.75 cm3 voxel within the tumour before (A) and after (B) three cycles of neoadjuvant chemotherapy. Triglyceride signal (1.3 p.p.m.) in-phase with choline-containing compounds (3.2 p.p.m.) is reduced in (B).
Figure 5
Figure 5
Cumulative proportions surviving in each group. The solid line shows the Kaplan–Meier survival curve for the neoadjuvant chemotherapy group and the dashed line is the survival curve for the control group. The vertical dashes are censored observations and the open symbols are deaths.
See this image and copyright information in PMC

References

    1. Aoki Y, Tomita M, Sato T, Watanabe M, Kase H, Fujita K, Kurata H, Tanaka K (2001) Neoadjuvant chemotherapy for patients younger than 50 y with high-risk squamous cell carcinoma of the cervix. Gynecol Oncol 83: 263–267 - PubMed
    1. Benedetti-Panici P, Greggi S, Scambia G, Amoroso M, Salerno MG, Maneschi F, Cutillo G, Paratore MP, Scorpiglione N, Mancuso S (1998) Long-term survival following neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Eur J Cancer 34: 341–346 - PubMed
    1. Benedetti-Panici P, Greggi S, Colombo A, Amoroso M, Smaniotto D, Giannarelli D, Amunni G, Raspagliesi F, Zola P, Mangioni C, Landoni F (2002) Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multi-center randomized trial. J Clin Oncol 20: 179–188 - PubMed
    1. Benedetti-Panici P, Scambia G, Baiocchi G, Gregi S, Ragusa G, Gallo A, Conte M, Battaglia F, Laurelli G, Rabitti C, Capelli A, Mancuso S (1991) Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer: prognostic factors for response and survival. Cancer 67: 372–379 - PubMed
    1. Blankenberg FG, Katsikis PD, Storrs RW, Beaulieu C, Spielman D, Chen JY, Naumovski L, Tait JF (1997) Quantitative analysis of apoptotic cell death using proton nuclear magnetic resonance spectroscopy. Blood 89: 3778–3786 - PubMed

MeSH terms